TABLE 5.
Season | Strain | Mean IC50 ± SD (nM)a
|
Outlier(s)/drug(s)b | NA mutationc | Accession no. | |
---|---|---|---|---|---|---|
Oseltamivir | Zanamivir | |||||
2004-2005 | B/Hong Kong/36/2005 | 1,778.25 ± 729.78d | 154.85 ± 47.47d | E/O, E/Z | R371K | EU879085 |
2004-2005 | B/Michigan/20/2005 | 10.80 ± 2.90e | 1.54 ± 0.27 | M/O | H274Y | CY015375 |
2004-2005 | B/California/5/2005 | 10.48 ± 1.62 | 8.65 ± 1.46 | M/O | I222T | EU879086 |
2004-2005 | B/California/4/2005 | 8.60 ± 1.93 | 3.73 ± 1.72 | M/O | T325I | EU879084 |
Mean IC50 ± SD values were calculated from data collected from at least three independent experiments.
E, extreme; M, mild; O, oseltamivir (IC50 values of >7.47 nM); Z, zanamivir (IC50 values of >11.29 nM).
Boldface type indicates the mutation in the NA active site.
A 407-fold increase in IC50 to oseltamivir and a 29-fold increase in IC50 to zanamivir compared to the IC50 values of the matching virus B/Hong Kong/45/2005 (accession no. ISDN127249).
A 4-fold increase in IC50 to oseltamivir compared to that of the matching virus B/Illinois/47/2005 (accession no. CY15376).